We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (βNGM Bioβ) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | -0.01 | -0.645161290323 | 1.55 | 2.2 | 1.5 | 1391399 | 1.59443325 | CS |
26 | 0.7958 | 106.933619995 | 0.7442 | 2.2 | 0.6002 | 1098793 | 1.35168465 | CS |
52 | -1.95 | -55.8739255014 | 3.49 | 3.75 | 0.6002 | 699443 | 1.5520637 | CS |
156 | -26.1 | -94.4283646889 | 27.64 | 30.13 | 0.6002 | 524246 | 7.93089697 | CS |
260 | -12.28 | -88.8567293777 | 13.82 | 32.12 | 0.6002 | 400967 | 10.66860782 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions